Effects of Creatine Supplementation in Breast Cancer Survivors
Lay Description
The purpose of this study is to test whether creatine supplements can accelerate improvements in strength and endurance associated with exercise in breast cancer survivors recently completing chemotherapy.
Category
- Cancers and Other Neoplasms
- Rehabilitation
- Womens Health
- Muscle, Bone and Cartilage
- Exercise
- Breast - Female
- Breast Neoplasm
- Cancer Survivors
- IRB Number
- 20190610HU
- NCT Number
- NCT04207359
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Between 18 Years and 75 Years
- Eligible Genders
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- 18-75 years of age
- Recent (within 6 months) completion of chemotherapy
- Willing to attend 3 exercise sessions per week via Zoom
- Able to take oral medications
- Participant is willing and able to provide consent to participating in the study
- Serum creatinine ≤ 1.5 x ULN or Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation.
Exclusion Criteria
- Physical indications where performing exercise may be limited and/or contraindicated
- Poorly-controlled hypertension (blood pressure > 160/95mmHg)
- Current tobacco use (within 6 months)
- Anabolic steroids use
- Pitting edema
- Currently undergoing infusion chemotherapy.
- History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation).
- Pregnant or plan to get pregnant during the study
- Recent (within one month) or anticipated treatment with corticosteroids (except for short term use during the time of chemotherapy), androgens, progestational agents, or other appetite stimulants
- Serum creatinine > 1.5 x ULN or Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation.
- Currently taking creatine supplements
Study Design
Arm Groups
Study Contact
Regulatory Point of Contact
Amber Gallegos
(210) 606-2437
gallegosa4@uthscsa.edu
Regulatory Point of Contact
Andrea Hansis-diarte
+1 (210) 617-5300
hansisdiarte@uthscsa.edu
Regulatory Point of Contact
Diana Jarbeau-may
(210) 617-5190
jarbeaumay@uthscsa.edu
Regulatory Point of Contact
Crisann Moon
(210) 288-0488
moonc1@uthscsa.edu
Regulatory Point of Contact
Darpan Patel
(210) 567-0362
pateld7@uthscsa.edu
Local Recruitment Point of Contact
Amber Gallegos
(210) 606-2437
gallegosa4@uthscsa.edu
Local Recruitment Point of Contact
Andrea Hansis-diarte
+1 (210) 617-5300
hansisdiarte@uthscsa.edu
Overall Recruitment Point of Contact
Angela Gonzalez
gonzaleza46@uthscsa.edu
Principal Investigator
Darpan Patel